# A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT02737332** · PHASE2 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 53 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Zytiga® (Abiraterone Acetate)
- **DRUG:** SoluMatrix™ (Abiraterone Acetate)

## Key facts

- **NCT ID:** NCT02737332
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-21
- **Primary completion:** 2017-02-27
- **Final completion:** 2017-02-27
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02737332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02737332, "A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02737332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*